TVTX Stock Overview
A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Travere Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.84 |
| 52 Week High | US$14.07 |
| 52 Week Low | US$5.12 |
| Beta | 0.71 |
| 11 Month Change | 50.53% |
| 3 Month Change | 74.93% |
| 1 Year Change | -7.02% |
| 33 Year Change | -45.62% |
| 5 Year Change | 6.91% |
| Change since IPO | 149.32% |
Recent News & Updates
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
Sep 10
Travere Therapeutics: Judgement Day Is Nigh For Sparsentan
Aug 30Recent updates
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
Sep 10Travere Therapeutics: Judgement Day Is Nigh For Sparsentan
Aug 30Shareholders May Be More Conservative With Travere Therapeutics, Inc.'s (NASDAQ:TVTX) CEO Compensation For Now
May 02Lacklustre Performance Is Driving Travere Therapeutics, Inc.'s (NASDAQ:TVTX) 29% Price Drop
Apr 20Travere Therapeutics: Restructuring Away From Disaster
Jan 30Travere Therapeutics (NASDAQ:TVTX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Jan 22Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 48% But Its Business Prospects Need A Lift Too
Dec 18New Forecasts: Here's What Analysts Think The Future Holds For Travere Therapeutics, Inc. (NASDAQ:TVTX)
Aug 08Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?
Jun 09It's Down 27% But Travere Therapeutics, Inc. (NASDAQ:TVTX) Could Be Riskier Than It Looks
May 05Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?
Feb 16Travere Therapeutics' FDA target action date for nephropathy treatment extended
Oct 13Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?
Oct 06Travere Therapeutics: Changes In The Risk-Reward Assessment
Sep 29Travere, CSL kidney disease drug sparsentan gets review in EU
Aug 22Travere Therapeutics GAAP EPS of -$1.05 misses by $0.14, revenue of $54.2M beats by $4.7M
Aug 04Travere Theraspeutics a new buy at Canaccord as a 'rare disease powerhouse'
Jul 14Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?
Jun 19Travere Therapeutics: Strong Sell, Ticking Time Bomb, We Are Passing
Apr 11Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?
Feb 07Travere Therapeutics: Tarpeyo's Approval Is Good News
Jan 31Does Travere Therapeutics (NASDAQ:TVTX) Have A Healthy Balance Sheet?
Oct 07Regulatory Uncertainty Holding Travere Therapeutics Down Despite PROTECT Study Success
Aug 30Shareholder Returns
| TVTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 33.8% | 0.7% | -0.8% |
| 1Y | -7.0% | 15.1% | 20.5% |
Return vs Industry: TVTX underperformed the US Biotechs industry which returned 13.9% over the past year.
Return vs Market: TVTX underperformed the US Market which returned 19.6% over the past year.
Price Volatility
| TVTX volatility | |
|---|---|
| TVTX Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TVTX's share price has been volatile over the past 3 months.
Volatility Over Time: TVTX's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 380 | Eric Dube | www.travere.com |
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company’s clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria.
Travere Therapeutics, Inc. Fundamentals Summary
| TVTX fundamental statistics | |
|---|---|
| Market cap | US$983.68m |
| Earnings (TTM) | -US$383.45m |
| Revenue (TTM) | US$177.64m |
5.5x
P/S Ratio-2.6x
P/E RatioIs TVTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TVTX income statement (TTM) | |
|---|---|
| Revenue | US$177.64m |
| Cost of Revenue | US$233.50m |
| Gross Profit | -US$55.86m |
| Other Expenses | US$327.59m |
| Earnings | -US$383.45m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.01 |
| Gross Margin | -31.44% |
| Net Profit Margin | -215.85% |
| Debt/Equity Ratio | 2,496.4% |
How did TVTX perform over the long term?
See historical performance and comparison